Fintel reports that on January 30, 2025, B. Riley Securities initiated coverage of Foghorn Therapeutics (NasdaqGM:FHTX) with ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.97% of ...

B. Riley issued their Q1 2025 earnings estimates for Customers Bancorp in a research note issued to investors on Monday, ...

Learn about the latest financial trends and strategies in our comprehensive article written by a financial expert.

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...

B. Riley reduced their Q1 2025 earnings per share estimates for shares of Onsemi in a report released on Friday, January 24th ...

B. Riley analyst Kyle Bauser raised the firm’s price target on ClearPoint Neuro (CLPT) to $20 from $15 and keeps a Buy rating ...

B. Riley analyst Mike Crawford upgraded Redwire (RDW) to Buy from Neutral with a price target of $27, up from $9.50. The firm increased fiscal ...

B. Riley has initiated Foghorn Therapeutics (NASDAQ:FHTX) at buy citing the company's development of SMARCA2 inhibitors to ...

Redwire Corp (NYSE:RDW) was upgraded to Buy from Neutral at financial services company B. Riley, which also hiked its price target on the space infrastructure provider to $27.00 from $9.50.

President Donald Trump plans to sign the Laken Riley Act into law as his administration's first piece of legislation.

In a battle of wills, Pat Riley always wins, and will wait it out until he wins — no matter the opponent or cost. The newly implemented collective bargaining agreement means more standoffs and ...